Literature DB >> 11040244

Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice.

H Honeck1, V Gross, B Erdmann, E Kärgel, R Neunaber, A F Milia, W Schneider, F C Luft, W H Schunck.   

Abstract

Cytochrome P450 (P450)-dependent arachidonic acid metabolites may act as mediators in the regulation of vascular tone and renal function. We studied arachidonic acid hydroxylase activities in renal microsomes from normotensive NMRI mice, desoxycorticosterone acetate (DOCA)-salt hypertensive mice, and DOCA-salt mice treated with either lovastatin or bezafibrate, both of which improve hemodynamics in this model. Control renal microsomes had arachidonic acid hydroxylase activities of 175+/-12 pmol. min(-1). mg(-1). The metabolites formed were 20- and 19-hydroxyarachidonic acid, representing approximately 80% and approximately 20% of the total hydroxylation. Treatment with DOCA-salt resulted in significantly decreased hydroxylase activities (to 84+/-4 pmol. min(-1). mg(-1)) of the total microsomal P450 content and a decrease in immunodetectable Cyp4a proteins. Lovastatin had no effect on these variables, whereas bezafibrate increased arachidonic acid hydroxylase activities to 163+/-12 pmol. min(-1). mg(-1). In situ hybridization with probes for Cyp4a-10, 12, and 14 revealed that Cyp4a-14 was the P450 isoform most strongly induced by bezafibrate. The expression was concentrated in the cortical medullary junction and was localized predominantly in the proximal tubules. In conclusion, these results suggest that the capacity to produce 20-hydroxyarachidonic acid is impaired in the kidneys of DOCA-salt hypertensive mice. Furthermore, bezafibrate may ameliorate hemodynamics in this model by restoring P450-dependent arachidonic acid hydroxylase activities. Lovastatin, on the other hand, exerts its effects via P450-independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040244     DOI: 10.1161/01.hyp.36.4.610

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

1.  Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation.

Authors:  Dominik N Muller; Cosima Schmidt; Eduardo Barbosa-Sicard; Maren Wellner; Volkmar Gross; Hantz Hercule; Marija Markovic; Horst Honeck; Friedrich C Luft; Wolf-Hagen Schunck
Journal:  Biochem J       Date:  2007-04-01       Impact factor: 3.857

Review 2.  Conflicting roles of 20-HETE in hypertension and renal end organ damage.

Authors:  Chao Zhang; George W Booz; Qing Yu; Xiaochen He; Shaoxun Wang; Fan Fan
Journal:  Eur J Pharmacol       Date:  2018-06-07       Impact factor: 4.432

Review 3.  20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension.

Authors:  Jan M Williams; Sydney Murphy; Marilyn Burke; Richard J Roman
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

Review 4.  Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.

Authors:  Fan Fan; Ying Ge; Wenshan Lv; Matthew R Elliott; Yoshikazu Muroya; Takashi Hirata; George W Booz; Richard J Roman
Journal:  Front Biosci (Landmark Ed)       Date:  2016-06-01

5.  Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension.

Authors:  Yiqiang Zhou; Pengcheng Luo; Hsin-Hsin Chang; Hui Huang; Tianxin Yang; Zheng Dong; Cong-Yi Wang; Mong-Heng Wang
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

6.  Cytochrome P450 1B1 gene disruption minimizes deoxycorticosterone acetate-salt-induced hypertension and associated cardiac dysfunction and renal damage in mice.

Authors:  Brett L Jennings; Anne M Estes; Larry J Anderson; Xiao R Fang; Fariborz A Yaghini; Zheng Fan; Frank J Gonzalez; William B Campbell; Kafait U Malik
Journal:  Hypertension       Date:  2012-10-29       Impact factor: 10.190

7.  A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury.

Authors:  Dominik N Muller; Juergen Theuer; Erdenechimeg Shagdarsuren; Eva Kaergel; Horst Honeck; Joon-Keun Park; Marija Markovic; Eduardo Barbosa-Sicard; Ralf Dechend; Maren Wellner; Torsten Kirsch; Anette Fiebeler; Michael Rothe; Hermann Haller; Friedrich C Luft; Wolf-Hagen Schunck
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

8.  Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension.

Authors:  Dexter L Lee; Justin L Wilson; Rong Duan; Tamaro Hudson; Ahmed El-Marakby
Journal:  PPAR Res       Date:  2011-12-07       Impact factor: 4.964

9.  Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis.

Authors:  Lijuan Li; Nan Li; Wei Pang; Xu Zhang; Bruce D Hammock; Ding Ai; Yi Zhu
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.